Physician profile
Jonathon B Posthumus
NPI 1255536553
$8,698.05
in general payments reported to CMS, 2019-2025
36 companies · $1,838 in 2025
The $1,838 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $766 · 2021: $923 · 2022: $1,108 · 2023: $1,473 · 2024: $1,330 · 2025: $1,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,572 · Education: $68.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,572.00 |
| Education | $68.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,881.66 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,565.35 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $858.56 | 2019-2025 | Dupixent |
| Genzyme Corporation | $619.14 | 2019-2025 | |
| Pfizer INC. | $419.85 | 2019-2023 | |
| Kaleo, INC. | $377.01 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $365.66 | 2020-2025 | Takhzyro, Cuvitru, Glassia |
| Novartis Pharmaceuticals Corporation | $331.41 | 2019-2025 | |
| Genentech USA, INC. | $272.97 | 2019-2025 | Xolair |
| Optinose US, INC. | $264.41 | 2019-2025 | |
| Grifols USA, LLC | $219.14 | 2019-2024 | Xembify, Gamunex-C |
| Amgen INC. | $205.93 | 2020-2025 | Tezspire |
| Csl Behring | $185.93 | 2019-2025 | Hizentra, Andembry |
| Pharming Healthcare, INC. | $175.95 | 2019-2025 | Ruconest |
| Incyte Corporation | $112.77 | 2022-2023 | Opzelura |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $110.01 | 2025 | Neffy |
| Leo Pharma INC. | $93.30 | 2023-2024 | Adbry |
| Biocryst US Sales Co., LLC | $85.66 | 2021 | |
| Covis Pharma Gmbh | $60.95 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $60.80 | 2025 | Alvesco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.71 | 2019-2021 | |
| Shire North American Group INC | $42.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $41.21 | 2019-2021 | |
| Ionis Pharmaceuticals, INC. | $40.60 | 2025 | Dawnzera |
| Sanofi-Aventis U.S. LLC | $40.07 | 2019-2020 | |
| Biocryst Pharmaceuticals, INC. | $31.66 | 2020 | |
| Sunovion Pharmaceuticals INC. | $22.28 | 2019 | |
| Aimmune Therapeutics, INC. | $20.52 | 2022 | |
| Phadia US INC. | $20.29 | 2023 | Immunocap |
| Merck Sharp & Dohme LLC | $19.55 | 2023 | |
| Lilly USA, LLC | $18.46 | 2024 | Ebglyss |
| Blueprint Medicines Corporation | $17.99 | 2023 | Ayvakit |
| Alk-Abello, INC | $17.59 | 2022 | |
| Circassia INC. | $15.69 | 2019 | |
| Galderma Laboratories, L.P. | $13.63 | 2025 | Nemluvio |
| Eyevance Pharmaceuticals LLC | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Posthumus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.